These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 24127063)

  • 1. Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression.
    Hou HA; Kuo YY; Tang JL; Chou WC; Yao M; Lai YJ; Lin CC; Chen CY; Liu CY; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Liu CW; Huang SY; Ko BS; Wu SJ; Tsay W; Chen YC; Tien HF
    Am J Hematol; 2014 Feb; 89(2):181-6. PubMed ID: 24127063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.
    Kanagal-Shamanna R; Luthra R; Yin CC; Patel KP; Takahashi K; Lu X; Lee J; Zhao C; Stingo F; Zuo Z; Routbort MJ; Singh RR; Fox P; Ravandi F; Garcia-Manero G; Medeiros LJ; Bueso-Ramos CE
    Oncotarget; 2016 Mar; 7(12):14251-8. PubMed ID: 26883102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
    Meggendorfer M; Bacher U; Alpermann T; Haferlach C; Kern W; Gambacorti-Passerini C; Haferlach T; Schnittger S
    Leukemia; 2013 Sep; 27(9):1852-60. PubMed ID: 23628959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression.
    Fernandez-Mercado M; Pellagatti A; Di Genua C; Larrayoz MJ; Winkelmann N; Aranaz P; Burns A; Schuh A; Calasanz MJ; Cross NC; Boultwood J
    Br J Haematol; 2013 Oct; 163(2):235-9. PubMed ID: 23889083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution.
    Lin CC; Hou HA; Chou WC; Kuo YY; Liu CY; Chen CY; Lai YJ; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Wu SJ; Tsay W; Chen YC; Tien HF
    Am J Hematol; 2014 Feb; 89(2):137-44. PubMed ID: 24115220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RUNX1 gene mutation in primary myelodysplastic syndrome--the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome.
    Chen CY; Lin LI; Tang JL; Ko BS; Tsay W; Chou WC; Yao M; Wu SJ; Tseng MH; Tien HF
    Br J Haematol; 2007 Nov; 139(3):405-14. PubMed ID: 17910630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.
    Thol F; Friesen I; Damm F; Yun H; Weissinger EM; Krauter J; Wagner K; Chaturvedi A; Sharma A; Wichmann M; Göhring G; Schumann C; Bug G; Ottmann O; Hofmann WK; Schlegelberger B; Heuser M; Ganser A
    J Clin Oncol; 2011 Jun; 29(18):2499-506. PubMed ID: 21576631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Only SETBP1 hotspot mutations are associated with refractory disease in myeloid malignancies.
    Winkelmann N; Schäfer V; Rinke J; Kaiser A; Ernst P; Scholl S; Hochhaus A; Ernst T
    J Cancer Res Clin Oncol; 2017 Dec; 143(12):2511-2519. PubMed ID: 28913558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SETBP1 mutation analysis in 944 patients with MDS and AML.
    Thol F; Suchanek KJ; Koenecke C; Stadler M; Platzbecker U; Thiede C; Schroeder T; Kobbe G; Kade S; Löffeld P; Banihosseini S; Bug G; Ottmann O; Hofmann WK; Krauter J; Kröger N; Ganser A; Heuser M
    Leukemia; 2013 Oct; 27(10):2072-5. PubMed ID: 23648668
    [No Abstract]   [Full Text] [Related]  

  • 10. FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia.
    Bains A; Luthra R; Medeiros LJ; Zuo Z
    Am J Clin Pathol; 2011 Jan; 135(1):62-9. PubMed ID: 21173125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.
    Inoue D; Kitaura J; Matsui H; Hou HA; Chou WC; Nagamachi A; Kawabata KC; Togami K; Nagase R; Horikawa S; Saika M; Micol JB; Hayashi Y; Harada Y; Harada H; Inaba T; Tien HF; Abdel-Wahab O; Kitamura T
    Leukemia; 2015 Apr; 29(4):847-57. PubMed ID: 25306901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: A meta-analysis.
    Shou LH; Cao D; Dong XH; Fang Q; Wu Y; Zhang Y; Fei JP; Xu BL
    PLoS One; 2017; 12(2):e0171608. PubMed ID: 28158286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression.
    Wu SJ; Tang JL; Lin CT; Kuo YY; Li LY; Tseng MH; Huang CF; Lai YJ; Lee FY; Liu MC; Liu CW; Hou HA; Chen CY; Chou WC; Yao M; Huang SY; Ko BS; Tsay W; Tien HF
    Am J Hematol; 2013 Nov; 88(11):E277-82. PubMed ID: 23861105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.
    Bally C; Adès L; Renneville A; Sebert M; Eclache V; Preudhomme C; Mozziconacci MJ; de The H; Lehmann-Che J; Fenaux P
    Leuk Res; 2014 Jul; 38(7):751-5. PubMed ID: 24836762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant isochromosome 17q and mutated
    Xu Q; Liu C; Zhang H; Liu H; Xue M; Zhang S; Liu B
    Int J Clin Exp Pathol; 2017; 10(9):9786-9792. PubMed ID: 31966863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognosis and risk factors for ASXL1 mutations in patients with newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
    Yang L; Wei X; Gong Y
    Cancer Med; 2024 Jan; 13(1):e6871. PubMed ID: 38146893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
    Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P
    Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of DTA mutation and co-occurring mutations in patients with myelodysplastic syndrome.
    Wang M; Chen P; Li D; Zhao M
    Mol Biol Rep; 2024 Sep; 51(1):985. PubMed ID: 39278886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SETBP1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
    Yao XY; Zhou JD; Yang J; Zhang W; Ma JC; Wen XM; Yao DM; Xu ZJ; Wu DH; He PF; Qian J; Lin J
    Pathol Res Pract; 2018 May; 214(5):706-712. PubMed ID: 29549983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing.
    Patnaik MM; Lasho TL; Finke CM; Hanson CA; King RL; Ketterling RP; Gangat N; Tefferi A
    Am J Hematol; 2016 May; 91(5):492-8. PubMed ID: 26874914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.